Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CymaBay Therapeutics (CBAYResearch Report) and BioSig Technologies (BSGMResearch Report) with bullish sentiments.

CymaBay Therapeutics (CBAY)

In a report released today, Sean Kim PhD from JonesTrading maintained a Buy rating on CymaBay Therapeutics, with a price target of $8.00. The company’s shares closed last Tuesday at $3.67.

According to, PhD is a 1-star analyst with an average return of -12.8% and a 40.9% success rate. PhD covers the Healthcare sector, focusing on stocks such as Satsuma Pharmaceuticals, Arcutis Biotherapeutics, and Phathom Pharmaceuticals.

Currently, the analyst consensus on CymaBay Therapeutics is a Strong Buy with an average price target of $9.00, a 145.9% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

BioSig Technologies (BSGM)

Noble Financial analyst Gregory Aurand maintained a Buy rating on BioSig Technologies today and set a price target of $2.00. The company’s shares closed last Tuesday at $0.44, close to its 52-week low of $0.25.

According to, Aurand is ranked #7959 out of 8123 analysts.

BioSig Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CBAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More